Diabetes, obesity and cancer: risk and anti-risk factors
https://doi.org/10.14341/2072-0351-5543
Abstract
Observable diabetes and obesity epidemics may result in alteration of cancer morbidity and mortality. This increasingly recognized problem is reviewed here from the perspective of interplay between factors that differently modify association of diabetes mellitus with malignant neoplasms. Heterogeneity and familial aspects of diabetes and obesity, genomic traits, anti-diabetic medications and weight-reducing treatment are important examples of such factors. Addressing them might promote development of efficient preventive measures.
References
1. Berger M. Risk of obesity in type II diabetes mellitus. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 4:S29-33.
2. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab. 2010 Jun;12(6):463-473.
3. Dedov II, Shestakova MV. Diabetes mellitus: diagnosis, treatment, prevention. Moscow: MIA; 2011. 808 p.
4. Dedov II, Mel'nichenko GA. Obesity. Moscow: MIA; 2006. 456 p.
5. Hjartåker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008;630:72-93.
6. Vasil'ev DA, Semenova NV, Bershteyn LM. Diabetes mellitus, glucose intolerance, and malignancies: the degree of a risk and interventional measures. Russian journal of oncology. 2008; (3):49-54.
7. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009 Dec;16(4):1103-1123. Epub 2009 Jul 20.
8. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes Care. 2010 Jul;33(7):1674-1685.
9. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist. 2011;16(6):726-729. Epub 2011 May 31.
10. Wotton CJ, Yeates DG, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia. 2011 Mar;54(3):527-534. Epub 2010 Nov 30.
11. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005 Jan;2(1):48-53.
12. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008 Dec 17;300(23):2754-2764.
13. Bershteyn LM, Merabishvili VM, Semenova NV, Karpova IA, Kovalevskiy AYu. Registry-based analysis of cancer and diabetes combination: prevalence and features. Voprosy oncologii. 2007; 53(3):285-290.
14. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med. 2010 Jul;27(7):791-797.
15. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-591.
16. Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, Buchan I. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010 Feb 1;126(3):692-702.
17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-1638.
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-2556.
19. Bershteyn LM. Rak gormonozavisimykh tkaney v sisteme osnovnykh neinfektsionnykh zabolevaniy cheloveka. Sankt- Petersburg: Eskulap; 2009. 180 p.
20. Herrera BM, Lindgren CM. The genetics of obesity. Curr Diab Rep. 2010 Dec;10(6):498-505.
21. Petrek JA, Peters M, Cirrincione C, Rhodes D, Bajorunas D. Is body fat topography a risk factor for breast cancer? Ann Intern Med. 1993; 118(5): 356-362.
22. Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008 Oct 11;372(9646):1281-1283.
23. Messier V, Karelis AD, Prud'homme D, Primeau V, Brochu M, Rabasa-Lhoret R. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity (Silver Spring). 2010 May;18(5):911-917. Epub 2009 Oct 22.
24. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Crosignani P, Bosi E, Luzi L, Ruotolo G, Perseghin G. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011 Jan;34(1):210-215. Epub 2010 Oct 11.
25. Manu P, Ionescu-Tirgoviste C, Tsang J, Napolitano BA, Lesser ML, Correll CU. Dysmetabolic Signals in "Metabolically Healthy" Obesity. Obes Res Clin Pract. 2012 Jan;6(1):e9-e20.
26. Zhang C, McFarlane C, Lokireddy S, Masuda S, Ge X, Gluckman PD, Sharma M, Kambadur R. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia. 2012 Jan;55(1):183-193. Epub 2011 Sep 17.
27. Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, Lynch GS. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol. 2011 Sep;301(3):R716-726. Epub 2011 Jun 15.
28. Enerbäck S. Brown adipose tissue in humans. Int J Obes (Lond). 2010 Oct;34 Suppl 1:S43-46.
29. Gunawardana SC, Piston DW. Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes. 2012 Mar;61(3):674-682. Epub 2012 Feb 7.
30. Townsend KL, Tseng YH. Brown adipose tissue: Recent insights into development, metabolic function and therapeutic potential. Adipocyte. 2012; 1(1): 13-24. DOI: 10.4161/adip.18951
31. Jones LP, Buelto D, Tago E, Owusu-Boaltey KE. Abnormal mammary adipose tissue environment of Brca1 mutant mice show a persistent deposition of highly vascularized multilocular adipocytes. J Cancer Sci Ther. 2011;S2:1-6. DOI: 10.4172/1948-5956.S2-004
32. Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, Muñoz- Martin M, Gómez-López G, Cañamero M, Mulero F, Pastor J, Martinez S, Romanos E, Mar Gonzalez-Barroso M, Rial E, Valverde AM, Bischoff JR, Serrano M. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 2012 Mar 7;15(3):382-394.
33. Berstein LM. Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol. 2008 Feb;4(1):23-39.
34. Berstein LM. Endocrinology of breast cancer: results, tasks and hopes. Expert Rev. Endocrinol. Metabol. 2011; 6(3): 293-297.
35. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010 Dec 9;363(24):2339-2350.
36. Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem. 2011 Feb;57(2):241-254. Epub 2010 Nov 30.
37. Ohshige T, Iwata M, Omori S, Tanaka Y, Hirose H, Kaku K, Maegawa H, Watada H, Kashiwagi A, Kawamori R, Tobe K, Kadowaki T, Nakamura Y, Maeda S. Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One. 2011;6(10):e26911. Epub 2011 Oct 26.
38. den Hoed M, Luan J, Langenberg C, Cooper C, Sayer AA, Jameson K, Kumari M, Kivimaki M, Hingorani AD, Grøntved A, Khaw KT, Ekelund U, Wareham NJ, Loos RJ. Evaluation of common genetic variants identified by GWAS for early onset and morbid obesity in population-based samples. Int J Obes (Lond). 2012 Mar 20. DOI: 10.1038/ijo.2012.34.
39. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimäki M, Humphries SE. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010 Jan 14;340:b4838. DOI: 10.1136/bmj.b4838.
40. Schmid R, Vollenweider P, Bastardot F, Vaucher J, Waeber G, Marques-Vidal P. Current Genetic Data Do Not Improve the Prediction of Type 2 Diabetes Mellitus: The CoLaus Study. J Clin Endocrinol Metab. 2012 Jul;97(7):E1338-1341. Epub 2012 Apr 24.
41. Salopuro T, Pulkkinen L, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M; Finnish Diabetes Prevention Study Group. Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. Int J Obes (Lond). 2005 Oct;29(10):1245-1251.
42. Ulybina YuM, Imyanitov EN, Vasil'ev DA, Bershteyn LM. Polimorfnye markery genov, opredelyayushchikh narusheniya zhirouglevodnogo obmena i insulinorezistentnost', u onkologicheskikh bol'nykh. Molekulyarnaya biologiya. 2008; 42(6):947-956.
43. Sainz J, Rudolph A, Hoffmeister M, Frank B, Brenner H, Chang-Claude J, Hemminki K, Försti A. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab. 2012 May;97(5):E845-851. Epub 2012 Mar 14.
44. Delahanty RJ, Beeghly-Fadiel A, Xiang YB, Long J, Cai Q, Wen W, Xu WH, Cai H, He J, Gao YT, Zheng W, Shu XO. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol. 2011 Nov 15;174(10):1115-1126. Epub 2011 Oct 5.
45. Li G, Chen Q, Wang L, Ke D, Yuan Z. Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls. Tumour Biol. 2012 Aug;33(4):1237-1243. doi: 10.1007/s13277-012-0372-9. Epub 2012 Mar 7.
46. Hemminki K, Li X, Sundquist J, Sundquist K. Obesity and familial obesity and risk of cancer. Eur J Cancer Prev. 2011 Sep;20(5):438-443.
47. Berstein LM. Macrosomy, obesity and cancer. NY: Nova Science Publishers. 1997; 189pp.
48. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548-555. Epub 2010 May 17.
49. Bershteyn LM, Boyarkina MP, Teslenko SYu, Vasil'ev DA. Familial diabetes frequency as a factor in diabetics suffering from cancer. Voprosy onkologii. 2011; 57(4):443-447.
50. Berstein LM, Boyarkina MP, Teslenko SY. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med Oncol. 2012 Jun;29(2):1308- 1313. Epub 2011 Feb 6.
51. Dedov II, Butrova SA, Berkovskaya MA. Potentsial'nye vozmozhnosti metformina v profilaktike i lechenii onkologicheskikh zabolevaniy u bol'nykh sakharnym diabetom 2 tipa. Ozhirenie i metabolizm. 2011; 1(26):40-50.
52. Bershteyn LM. Biguanidy: ekspansiya v prakticheskuyu onkologiyu (proshloe i nastoyashchee). Sankt-Petersburg: Eskulap; 2010. 144 p.
53. Berstein L.M. Metformin and cancer mortality. Diabetes mellitus. 2010;(3):66-70.
54. Anisimov VN. Antidiabeticheskiy biguanid metformin kak geroprotektor i antikantserogen. Ozhirenie i metabolizm. 2011; 3(28):18-24.
55. Appleyard MV, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM, Fleming S, Alessi DR, Thompson AM. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer. 2012 Mar 13;106(6):1117-1122. doi: 10.1038/bjc.2012.56. Epub 2012 Feb 23.
56. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012 Mar 29;48(3):R31-43. Print 2012.
57. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012 Jan;35(1):119-124. Epub 2011 Nov 18.
58. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G. Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. Oncologist. 2012;17(6):813-822. Epub 2012 May 29.
59. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer. Horm Cancer. 2012 Aug;3(4):137-146. doi: 10.1007/ s12672-012-0112-z. Epub 2012 Apr 24.
60. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res. 2012 Jan 1;18(1):40-50.
61. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009 Dec;46(4):279-284. Epub 2008 Dec 10.
62. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012 Mar;55(3):644-653. Epub 2012 Jan 6.
63. Boyle P. Northern European database study of insulin and cancer risk. American Diabetes Association (ADA) 2012 Scientific Sessions; June 11, 2012; Philadelphia, PA. Abstract CT-SY13.
64. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabol. Syndrome: Clin. Res. & Reviews.2008; (2): 47-57. DOI: 10.1016/j.dsx.2007.11.002
65. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucoselowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. 2012 Mar;55(3):654-665. Epub 2011 Nov 30.
66. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012 Jan;97(1):121- 131. Epub 2011 Oct 26.
67. Aroda VR, Henry RR, Han J, Huang W, Deyoung MB, Darsow T, Hoogwerf BJ. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clin Ther. 2012 Jun;34(6):1247-1258.e22. doi: 10.1016/j. clinthera.2012.04.013. Epub 2012 May 18.
68. Levri K.M., Slaymaker E., Last A,Yeh J, Ference J, D'Amico F, Wilson SA. Metformin as Treatment for Overweight and Obese Adults: A Systematic Review. Ann Fam Med. 2005 Sep- Oct;3(5):457-461.
69. Dilman VM, Berstein LM, Yevtushenko TP, Tsyrlina YV, Ostroumova MN, Bobrov YuF, Revskoy SYu, Kovalenko IG, Simonov NN. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch. 1988;58(3):175-183.
70. Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012 Apr 15;118(8 Suppl):2277-2287. doi: 10.1002/cncr.27466.
71. Veerman JL, Barendregt JJ, Forster M, Vos T. Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS One. 2011;6(10):e26051. Epub 2011 Oct 27.
72. Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011 Jul;65(4):286-292. Epub 2011 Jun 12. 73. Yashkov YuI. Khirurgicheskie metody lecheniya ozhireniya. In: Obesity(ed. by Dedov II, Mel'nichenko GA). Moscow: MIA; 2004. 407-430. 74. Dixon JB, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011 Jun;28(6):628-642. doi: 10.1111/j.1464- 5491.2011.03306.x. 75. de la Cruz-Muñoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, Lipshultz SE, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and prediabetes among morbidly obese multiethnic adults: long-term results. J Am Coll Surg. 2011 Apr;212(4):505-511; discussion 512-513. 76. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009 Jul;10(7):653-662. Epub 2009 Jun 24. 77. Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011 May 1;117(9):1788-1799. doi: 10.1002/cncr.25738. Epub 2010 Nov 29.
Review
For citations:
Bershteyn L.M. Diabetes, obesity and cancer: risk and anti-risk factors. Diabetes mellitus. 2012;15(4):81-88. (In Russ.) https://doi.org/10.14341/2072-0351-5543
Views:
1380
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
